Meet your clinical, economic, and regulatory needs throughout a product's lifecycle using U.S. real world solutions.
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreBringing together unparalleled healthcare data, advanced analytics, innovative technologies, and healthcare expertise to create intelligent connections that speed the development and commercialization of innovative medicines to improve patient lives.
Learn MoreAccelerate digital innovation to enable smarter decisions that reduce cost, modernize patient and consumer engagement, and improve health outcomes.
Learn MoreA curation of IQVIA's best thinking on topics and trends driving change, disruption, and progress in the United States healthcare market.
LEARN MOREGet the latest insights on our life sciences, healthcare, and medical technology solutions in the United States. Follow our blog today!
LEARN MORE"Aligning legislative requirements, payer expectations regarding pricing and evidence, and meeting patients’ needs is now crucial for successful launches.
Learn moreThe use of external comparators (ECs) in drug development is on the rise, fueled by real-world data (RWD) and advancements in personalized medicine. Notably, the period from 2015 to 2019 saw a 22% increase in RWD-based EC usage. This upward trend is expected to continue, especially following the FDA’s February 2023 draft guidance, which advocates for a nuanced, case-by-case assessment of EC cohort designs.
While EC studies can significantly augment product lifecycles, from streamlining clinical trial design to strengthening real-world evidence (RWE) for payor negotiations and market positioning, the question arises: How can sponsors effectively advocate for their utilization to address the needs of a drug development program?
Meet your clinical, economic, and regulatory needs throughout a product's lifecycle using U.S. real world solutions.